Premaitha Health has signed an agreement with a new laboratory partner to offer an NIPT screening solution in a new East Asian territory for Premaitha.
The Partner is a private reference laboratory, which will provide the NIPT screening solution to its network of hospitals and clinics in the region. The installation of the laboratory is set to be completed in H1 2018. The Partner will be operating in an already established NIPT market with attractive market dynamics and growth prospects.
Dr Stephen Little, CEO of Premaitha Health, commented: “We are delighted to announce a further new international territory for Premaitha, which provides entry into another high growth market for NIPT. Despite Tuesday’s judgment, the impact of which is limited to the UK, we continue to expand Premaitha’s footprint through our geographic diversification strategy into territories unaffected by Illumina’s patents.”